Yunnan Biovalley Pharmaceutical Co (BJSE:920266) EPS (Basic): ¥-0.32 (TTM As of Mar. 2026)

What is Yunnan Biovalley Pharmaceutical Co EPS (Basic)?

Yunnan Biovalley Pharmaceutical Co BJSE:920266 64 EPS (Basic) is ¥-0.32 as of Mar. 2026. GuruFocus rates BJSE:920266 with a GF Score™ of 64/100 and a GF Value™ of ¥7.65 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Yunnan Biovalley Pharmaceutical Co's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was ¥-0.04. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-0.32.

Yunnan Biovalley Pharmaceutical Co's EPS (Diluted) for the three months ended in Mar. 2026 was ¥-0.04. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-0.32.

Yunnan Biovalley Pharmaceutical Co's EPS without NRI for the three months ended in Mar. 2026 was ¥-0.04. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.29.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Yunnan Biovalley Pharmaceutical Co's highest 3-Year average EPS without NRI Growth Rate was 71.10% per year. The lowest was -34.90% per year. And the median was -3.50% per year.

Yunnan Biovalley Pharmaceutical Co (BJSE:920266) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Yunnan Biovalley Pharmaceutical Co EPS (Basic) Related Terms

Yunnan Biovalley Pharmaceutical Co EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Yunnan Biovalley Pharmaceutical Co's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yunnan Biovalley Pharmaceutical Co EPS (Basic) Chart

Yunnan Biovalley Pharmaceutical Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EPS (Basic)

Get a 7-Day Free Trial

0.67

-0.39

-0.10

-0.60

-0.42

Yunnan Biovalley Pharmaceutical Co Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EPS (Basic)	Get a 7-Day Free Trial															-0.14	-0.09	-0.06	-0.13	-0.04

64GF Score

Yunnan Biovalley Pharmaceutical Co Ltd BJSE:920266

EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Yunnan Biovalley Pharmaceutical Co EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Yunnan Biovalley Pharmaceutical Co's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-51.578	-	0)	/	122.804
	=	-0.42

Yunnan Biovalley Pharmaceutical Co's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-4.695	-	0)	/	117.380
	=	-0.04

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-0.32

Frequently Asked Questions Learn more about EPS (Basic) →

What does a EPS (Basic) of ¥-0.32 mean?

Yunnan Biovalley Pharmaceutical Co (BJSE:920266) has a EPS (Basic) of ¥-0.32 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Yunnan Biovalley Pharmaceutical Co and its competitors.

Is Yunnan Biovalley Pharmaceutical Co's EPS (Basic) too high?

Yunnan Biovalley Pharmaceutical Co's current EPS (Basic) is ¥-0.32. Overall, Yunnan Biovalley Pharmaceutical Co has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Yunnan Biovalley Pharmaceutical Co's EPS (Basic) compare to ZTS?

Yunnan Biovalley Pharmaceutical Co's EPS (Basic) of ¥-0.32 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Basic) for a Drug Manufacturers company?

A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Basic) mean?

A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Yunnan Biovalley Pharmaceutical Co and its competitors. Yunnan Biovalley Pharmaceutical Co's current EPS (Basic) is ¥-0.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Yunnan Biovalley Pharmaceutical Co stock overvalued right now?

Based on GuruFocus' analysis, Yunnan Biovalley Pharmaceutical Co (BJSE:920266) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥7.65, compared to a current price of ¥6.22 — trading 18.7% below its estimated fair value. The current EPS (Basic) is ¥-0.32. Yunnan Biovalley Pharmaceutical Co's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Basic) calculated?

EPS (Basic) is calculated from a company's financial statements. For Yunnan Biovalley Pharmaceutical Co (BJSE:920266), the current EPS (Basic) is ¥-0.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Yunnan Biovalley Pharmaceutical Co (BJSE:920266) Overvalued in 2026?

Based on GuruFocus' analysis, Yunnan Biovalley Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥6.22 is trading 18.7% below its estimated GF Value™ of ¥7.65. GuruFocus considers Yunnan Biovalley Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for BJSE:920266:

EPS (Basic): ¥-0.32
GF Value™: ¥7.65 vs. price of ¥6.22 (18.7% below fair value)
GF Score™: 64/100 with 3 warning signs

No single metric tells the full story. See the BJSE:920266 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Yunnan Biovalley Pharmaceutical Co Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies BJSE:920478 BJSE:920230 BJSE:920367 BJSE:920433 BJSE:920566 SZSE:300391 BJSE:920017 SHSE:600080 SZSE:002817 SHSE:603168 XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692

Address No. 999 Biological Valley Street, Majinpu New District, High-tech Zone, Yunnan Province, Kunming City, CHN, 650500

Website http://ynswgen.biovalley.cn

Yunnan Biovalley Pharmaceutical Co Ltd engages in research and development, production, and marketing of pharmaceuticals and health care based on herbal medicines. The products on the market include breviscapine injection, breviscapine Shengmai capsules, breviscapine tablets, breviscapine dripping pills, Erigeron Capsules, Erigeron Soft Capsules.

64GF Score

Get the complete analysis for BJSE:920266

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥6.22

Price

¥7.65

GF Value

View BJSE:920266 Analysis

See EPS (Basic) data for all stocks →